The National Evaluation System for health Technology Coordinating Center (NESTcc) has made strides in achieving its 2019 Strategic Priorities, including preparing for the launch of NEST 1.0 by the end of the year. This multi-stakeholder panel will highlight the strategic importance of programmatic advancements this year—NESTcc’s expanding role in active surveillance, the launch of the increased test-case portfolio, and the development of frameworks to support high-quality data and methods across the NESTcc Data Network. In addition, the panel will discuss the importance of the upcoming launch of NEST 1.0 to accept and operationalize externally sponsored projects. NESTcc Executive Director Dr. Rachael Fleurence will introduce the panel composed of NESTcc Governing Committee members and provide an overview of NESTcc advances since last year’s Annual Public Forum and the vision for NESTcc 1.0. Following Dr. Fleurence, Dr. Jeff Shuren will provide the U.S. Food and Drug Administration (FDA) perspective on NESTcc’s recent milestones, and expectations for the future through NEST 1.0. Providing the perspective of a NESTcc Network Collaborator, Dr. Harlan Krumholz of Yale-New Haven Hospital will discuss the NESTcc Data Network, as well as his perspective as a member of the NESTcc Active Surveillance Task Force. Finally, Diane Wurzburger of GE Healthcare will also discuss the expectations for the launch of NEST 1.0, along with the impact of the advancements of the Data Network for industry stakeholders.
- Rachael Fleurence, PhD (moderator)
- Harlan Krumholz, MD, SM
- Jeff Shuren, MD, JD
- Diane Wurzburger, JD